ZA200802740B - Dengue virus capsid protein which induces a protective response and pharmaceutical composition - Google Patents

Dengue virus capsid protein which induces a protective response and pharmaceutical composition

Info

Publication number
ZA200802740B
ZA200802740B ZA200802740A ZA200802740A ZA200802740B ZA 200802740 B ZA200802740 B ZA 200802740B ZA 200802740 A ZA200802740 A ZA 200802740A ZA 200802740 A ZA200802740 A ZA 200802740A ZA 200802740 B ZA200802740 B ZA 200802740B
Authority
ZA
South Africa
Prior art keywords
induces
pharmaceutical composition
capsid protein
dengue virus
protective response
Prior art date
Application number
ZA200802740A
Other languages
English (en)
Inventor
Lazo Vazquez Laura
Lopez Abarrategui Carlos
Vazquez Ramundo Susana
Guillen Nieto Gerardo Enrique
Zulueta Morales Aida
Hermida Cruz Lisset
La Caridad Sierra Vazquez Beatriz De
Valdez Prado Iris
Guzman Tirado Maria Guadalupe
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of ZA200802740B publication Critical patent/ZA200802740B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA200802740A 2005-09-16 2008-03-27 Dengue virus capsid protein which induces a protective response and pharmaceutical composition ZA200802740B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal

Publications (1)

Publication Number Publication Date
ZA200802740B true ZA200802740B (en) 2008-12-31

Family

ID=40132555

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802740A ZA200802740B (en) 2005-09-16 2008-03-27 Dengue virus capsid protein which induces a protective response and pharmaceutical composition

Country Status (17)

Country Link
US (1) US7790173B2 (ko)
EP (1) EP1944038B1 (ko)
JP (1) JP5657204B2 (ko)
KR (2) KR20130100026A (ko)
CN (1) CN101304760B (ko)
AR (1) AR058049A1 (ko)
AU (1) AU2006291863B2 (ko)
BR (1) BRPI0616224B8 (ko)
CA (1) CA2622827C (ko)
CU (1) CU23578A1 (ko)
DK (1) DK1944038T3 (ko)
ES (1) ES2444691T3 (ko)
MY (2) MY161452A (ko)
PT (1) PT1944038E (ko)
RU (1) RU2008114841A (ko)
WO (1) WO2007031034A1 (ko)
ZA (1) ZA200802740B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
WO2009152147A2 (en) * 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
WO2012178196A2 (en) * 2011-06-24 2012-12-27 La Jolla Institute For Allergy And Immunology Protection against dengue virus and prevention of severe dengue disease
IN2015DN02893A (ko) 2012-10-04 2015-09-11 Univ Leland Stanford Junior
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
WO2016130321A1 (en) * 2015-02-09 2016-08-18 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018169550A1 (en) * 2017-03-17 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time rt-pcr assay for detection of dengue, chikungunya, and zika viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ATE186744T1 (de) 1991-09-19 1999-12-15 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
AU716676B2 (en) * 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
AU2933797A (en) 1996-05-10 1997-12-05 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
ATE291032T1 (de) 1997-08-11 2005-04-15 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide
RU2208635C2 (ru) * 1997-10-08 2003-07-20 ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
AU780308B2 (en) 1999-04-30 2005-03-17 J. Craig Venter Institute, Inc. Neisseria genomic sequences and methods of their use
ES2523168T3 (es) * 2001-05-22 2014-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
AU2003300831A1 (en) 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
JP5657204B2 (ja) 2015-01-21
MY149395A (en) 2013-08-30
MY161452A (en) 2017-04-14
EP1944038A1 (en) 2008-07-16
KR101350318B1 (ko) 2014-01-14
WO2007031034A1 (es) 2007-03-22
RU2008114841A (ru) 2009-10-27
CN101304760B (zh) 2013-03-13
ES2444691T3 (es) 2014-02-26
US20080311157A1 (en) 2008-12-18
DK1944038T3 (en) 2014-03-03
US7790173B2 (en) 2010-09-07
BRPI0616224A2 (pt) 2013-02-19
CA2622827A1 (en) 2007-03-22
CU23578A1 (es) 2010-09-30
KR20130100026A (ko) 2013-09-06
AU2006291863B2 (en) 2012-09-20
AU2006291863A1 (en) 2007-03-22
BRPI0616224B1 (pt) 2019-01-15
PT1944038E (pt) 2014-02-21
CA2622827C (en) 2015-12-15
CN101304760A (zh) 2008-11-12
AR058049A1 (es) 2008-01-23
JP2009507864A (ja) 2009-02-26
EP1944038B1 (en) 2013-11-27
BRPI0616224B8 (pt) 2021-05-25
KR20080048068A (ko) 2008-05-30

Similar Documents

Publication Publication Date Title
ZA200802740B (en) Dengue virus capsid protein which induces a protective response and pharmaceutical composition
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
IL189329A0 (en) Vaccination against dengue virus infection
PL1894567T3 (pl) Środki farmaceutyczne do podawania skojarzonego oraz ich zastosowanie
IL215102A0 (en) A heteroaryl benzamide derivative and a pharmaceutical composition containing it
EP1898922A4 (en) MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1857489A4 (en) MICROPARTICLE AND PHARMACEUTICAL COMPOSITION
DK1909764T3 (da) Farmaceutisk sammensætninger omfattende levetiracetam og fremgangsmåde til deres fremstilling
PT2589602T (pt) Desenvolvimento de componentes de vacina contra o vírus da dengue
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
EP1781308A4 (en) NATURAL ANTIVIRUS AND COMPOSITION CONTAINING SAME
GB0516069D0 (en) Pharmaceutical and use thereof
IL187534A0 (en) Thiazole derivatives, use thereof and pharmaceutical compositions containing them
LT1951663T (lt) (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos
IL221395A0 (en) Pharmaceutical compositions comprising alpha ketoamide derivatives and uses thereof
EP1893233A4 (en) PEPTIDES AND THERAPEUTIC VACCINES
EP1765386A4 (en) NS5 DOMAINE OF HEPATITIS C TRUNCH VIRUS AND HYBRID PROTEINS COMPRISING THE SAME
EP1884510A4 (en) N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
HK1109069A1 (en) Vaccine composition against hepatitis c virus
EP1942115A4 (en) AGGLUTINABLE GLP-1 ANALOGUE AND PROLONGED RELEASE PHARMACEUTICAL COMPOSITION
HK1099777A1 (en) Isolated proteins from a traditional chinese medicine yuzhu and use thereof
EP1937292A4 (en) LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
TWI371272B (en) Substituted propanamide derivatives and pharmaceutical compositions thereof